Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
AUTL Autolus Therapeutics	$1.51	$1.58	$1.18 ▼ $2.70	$401.90M	2.02	1.20 million shs	843,810 shs
DTIL Precision BioSciences	$6.81	$7.10	$3.53 ▼ $8.82	$175.70M	1.3	358,694 shs	431,067 shs
TBIO Telesis Bio	$0.00	$0.03	$0.00 ▼ $0.30	$2K	2.27	1,432 shs	16 shs
VYGR Voyager Therapeutics	$3.72	$3.80	$2.83 ▼ $5.55	$224.76M	1.25	442,593 shs	664,909 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
AUTL Autolus Therapeutics	0.00%	-3.21%	-11.18%	+7.86%	-26.34%
DTIL Precision BioSciences	0.00%	+11.64%	-5.81%	+4.45%	+42.17%
TBIO Telesis Bio	0.00%	0.00%	0.00%	-98.04%	-99.00%
VYGR Voyager Therapeutics	0.00%	+6.29%	-2.11%	-4.12%	+25.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences	$1.71	$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	N/A
AUTL Autolus Therapeutics	$1.51	$1.58	$1.18 ▼ $2.70	$401.90M	2.02	1.20 million shs	843,810 shs
DTIL Precision BioSciences	$6.81	$7.10	$3.53 ▼ $8.82	$175.70M	1.3	358,694 shs	431,067 shs
TBIO Telesis Bio	$0.00	$0.03	$0.00 ▼ $0.30	$2K	2.27	1,432 shs	16 shs
VYGR Voyager Therapeutics	$3.72	$3.80	$2.83 ▼ $5.55	$224.76M	1.25	442,593 shs	664,909 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
AUTL Autolus Therapeutics	0.00%	-3.21%	-11.18%	+7.86%	-26.34%
DTIL Precision BioSciences	0.00%	+11.64%	-5.81%	+4.45%	+42.17%
TBIO Telesis Bio	0.00%	0.00%	0.00%	-98.04%	-99.00%
VYGR Voyager Therapeutics	0.00%	+6.29%	-2.11%	-4.12%	+25.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	0.00	N/A	N/A	N/A
AUTL Autolus Therapeutics	2.89	Moderate Buy	$8.75	479.47% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	373.57% Upside
TBIO Telesis Bio	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	343.55% Upside

Current Analyst Ratings Breakdown

Latest VYGR, APTO, AUTL, TBIO, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/9/2026	DTIL Precision BioSciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/29/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/27/2026	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
5/26/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/14/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/14/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $10.00
5/8/2026	DTIL Precision BioSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/29/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/20/2026	AUTL Autolus Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
4/17/2026	DTIL Precision BioSciences	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00

(Data available from 6/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
AUTL Autolus Therapeutics	$75.39M	5.33	N/A	N/A	$0.67 per share	2.25
DTIL Precision BioSciences	$34.26M	5.13	N/A	N/A	$4.03 per share	1.69
TBIO Telesis Bio	$225.09M	0.00	N/A	N/A	$0.14 per share	0.01
VYGR Voyager Therapeutics	$40.37M	5.57	N/A	N/A	$3.53 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
AUTL Autolus Therapeutics	-$287.53M	-$1.09	N/A	N/A	N/A	-311.98%	-128.59%	-46.25%	8/11/2026 (Estimated)
DTIL Precision BioSciences	-$45.72M	-$3.67	N/A	N/A	N/A	-96.73%	-85.37%	-37.34%	8/6/2026 (Estimated)
TBIO Telesis Bio	-$47.72M	-$20.52	N/A	N/A	N/A	-336.59%	N/A	-61.89%	8/6/2026 (Estimated)
VYGR Voyager Therapeutics	-$119.72M	-$1.97	N/A	N/A	N/A	-319.61%	-55.97%	-43.12%	8/5/2026 (Estimated)

Latest VYGR, APTO, AUTL, TBIO, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2026	Q1 2026	AUTL Autolus Therapeutics	-$0.29	-$0.27	+$0.02	-$0.27	$26.27 million	$26.22 million
5/7/2026	Q1 2026	VYGR Voyager Therapeutics	-$0.54	-$0.47	+$0.07	-$0.47	$8.79 million	$1.19 million
5/5/2026	Q1 2026	DTIL Precision BioSciences	-$0.6550	-$0.75	-$0.0950	-$0.75	$4.05 million	$10.84 million
3/27/2026	Q4 2025	AUTL Autolus Therapeutics	-$0.27	-$0.34	-$0.07	-$0.34	$23.92 million	$24.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
TBIO Telesis Bio	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
AUTL Autolus Therapeutics	N/A	5.80	5.28
DTIL Precision BioSciences	0.29	14.02	14.02
TBIO Telesis Bio	N/A	1.23	1.06
VYGR Voyager Therapeutics	N/A	8.42	8.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
AUTL Autolus Therapeutics	72.83%
DTIL Precision BioSciences	37.99%
TBIO Telesis Bio	37.63%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
AUTL Autolus Therapeutics	25.70%
DTIL Precision BioSciences	2.70%
TBIO Telesis Bio	24.50%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
AUTL Autolus Therapeutics	330	266.16 million	197.75 million	Optionable
DTIL Precision BioSciences	200	25.80 million	25.11 million	No Data
TBIO Telesis Bio	200	1.80 million	1.36 million	No Data
VYGR Voyager Therapeutics	100	60.42 million	52.75 million	Optionable

VYGR, APTO, AUTL, TBIO, and DTIL Headlines

Recent News About These Companies

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 11, 2026 | globenewswire.com

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

June 10, 2026 | theglobeandmail.com

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

June 10, 2026 | tipranks.com

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

June 9, 2026 | finance.yahoo.com

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

June 1, 2026 | markets.businessinsider.com

Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy

June 1, 2026 | tipranks.com

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease

June 1, 2026 | globenewswire.com

What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs

May 20, 2026 | finance.yahoo.com

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

May 13, 2026 | markets.businessinsider.com

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026

May 13, 2026 | globenewswire.com

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

May 7, 2026 | zacks.com

Voyager Reports First Quarter 2026 Financial and Operating Results

May 7, 2026 | globenewswire.com

H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)

May 1, 2026 | theglobeandmail.com

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

April 28, 2026 | markets.businessinsider.com

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease

April 27, 2026 | globenewswire.com

Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026

April 13, 2026 | seekingalpha.com

Alfred Sandrock Sells 11,511 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock

April 4, 2026 | insidertrades.com

Voyager Therapeutics (VYGR) price target increased by 12.22% to 17.17

March 27, 2026 | msn.com

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

March 23, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)

March 19, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VYGR, APTO, AUTL, TBIO, and DTIL Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Autolus Therapeutics NASDAQ:AUTL

$1.51 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.54 +0.03 (+1.99%)

As of 07:34 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Precision BioSciences NASDAQ:DTIL

$6.81 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$6.98 +0.17 (+2.44%)

As of 07:00 AM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Telesis Bio NASDAQ:TBIO

$0.0010 0.00 (0.00%)

As of 06/18/2026

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Voyager Therapeutics NASDAQ:VYGR

$3.72 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$3.71 -0.01 (-0.27%)

As of 07:00 AM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, APTO, AUTL, TBIO, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, APTO, AUTL, TBIO, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, APTO, AUTL, TBIO, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VYGR, APTO, AUTL, TBIO, and DTIL Company Descriptions

Aptose Biosciences NASDAQ:APTO

Autolus Therapeutics NASDAQ:AUTL

Precision BioSciences NASDAQ:DTIL

Telesis Bio NASDAQ:TBIO

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools